Lexeo Therapeutics reported net income of -$26.02M for the quarter ended Jun 2026. This income statement covers 16 quarters of results from Sep 2022 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 1.59M | 1.61M | 1.61M | 1.62M | 1.63M | 5.35M | 32.93M | 33.04M | 33.06M | 33.07M | 33.19M | 43.57M | 54.93M | 53.65M | 74.09M | 78.62M |
| Revenue & cost | ||||||||||||||||
| Revenue | 0.53M | |||||||||||||||
| Operating items | ||||||||||||||||
| Research & DevelopmentR&D | 15.36M | 11.39M | 16.44M | 11.24M | 17.25M | 8.21M | 15.74M | 16.56M | 23.42M | 18.37M | 17.17M | 14.72M | 15.70M | 15.70M | 19.03M | |
| Wages, Salaries and OtherWages | 0.35M | 0.28M | 0.42M | 0.31M | 0.33M | 0.34M | 0.45M | 0.42M | 0.46M | |||||||
| Selling, General & AdministrativeSG&A | 2.65M | 3.81M | 2.85M | 2.74M | 3.03M | 6.76M | 7.55M | 6.99M | 8.12M | 9.02M | 16.63M | 15.97M | 5.95M | 6.91M | 6.63M | 8.99M |
| Restructuring CostsRestructuring | 4.89M | 3.96M | 4.34M | 11.80M | 12.56M | 13.93M | 2.87M | 9.32M | 4.71M | 6.95M | ||||||
| Other Operating ExpensesOther Opex | -4.89M | -3.96M | -4.34M | -11.80M | -12.56M | -13.93M | -2.87M | 6.89M | -4.71M | -6.95M | ||||||
| Operating ExpensesOpex | 18.01M | 15.20M | 19.29M | 13.97M | 20.27M | 14.97M | 23.29M | 23.55M | 31.54M | 27.38M | 33.80M | 30.69M | 21.65M | 23.12M | 22.33M | 28.02M |
| Operating IncomeOp. Inc | -17.48M | -15.20M | -19.29M | -13.97M | -20.27M | -14.97M | -23.29M | -23.55M | -31.54M | -27.38M | -33.80M | -30.69M | -21.65M | -23.12M | -22.33M | -28.02M |
| EBIT | -17.48M | -15.20M | -19.29M | -13.97M | -20.27M | -14.97M | -23.29M | -23.55M | -31.54M | -27.38M | -33.80M | -30.69M | -21.65M | -23.12M | -22.33M | -28.02M |
| Non-operating items | ||||||||||||||||
| Non Operating Interest Expenses | 0.03M | 0.05M | 0.05M | 0.05M | 0.05M | 0.05M | 0.04M | 0.04M | 0.04M | 0.03M | 0.03M | 0.03M | 0.02M | 0.02M | 0.02M | 0.01M |
| Non Operating Investment Income | 0.05M | 0.04M | -0.33M | -0.16M | ||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.46M | 0.68M | 0.69M | 0.59M | 0.49M | 1.10M | 1.65M | 2.35M | 2.09M | 1.47M | 1.19M | 1.27M | 1.46M | 2.21M | 2.11M | 2.19M |
| Other Non Operating IncomeOther Non Op Inc. | -0.00M | -0.00M | 0.00M | -0.01M | -0.01M | -0.00M | -0.00M | 1.45M | -0.00M | -0.01M | -0.01M | -5.50M | -0.00M | -0.01M | ||
| Non Operating IncomeNon Op. Inc. | 0.43M | 0.62M | 0.63M | 0.53M | 0.17M | 0.79M | 1.61M | 2.31M | 2.05M | 1.46M | 1.15M | 4.58M | 1.36M | 2.20M | 2.14M | 2.15M |
| Net income details | ||||||||||||||||
| EBT | -17.05M | -14.58M | -18.66M | -13.44M | -20.11M | -14.19M | -21.68M | -21.24M | -29.49M | -25.92M | -32.66M | -26.10M | -20.28M | -20.92M | -20.20M | -25.87M |
| Profit After TaxPAT | -17.05M | -14.60M | -18.66M | -13.44M | -20.11M | -14.19M | -21.68M | -21.24M | -29.49M | -26.03M | -32.66M | -26.10M | -20.28M | -20.96M | -20.20M | -26.02M |
| Income from Non-Controlling InterestsInc. Minority | -0.27M | -0.26M | ||||||||||||||
| Income from Continuing OperationsIncome (Continuing) | -17.05M | -14.58M | -18.66M | -13.44M | -20.11M | -14.19M | -21.68M | -21.24M | -29.49M | -25.92M | -32.66M | -26.10M | -20.28M | -20.92M | -20.20M | -25.87M |
| Consolidated Net IncomeConsol Net Inc. | -17.05M | -14.58M | -18.66M | -13.44M | -20.11M | -14.19M | -21.68M | -21.24M | -29.49M | -25.92M | -32.66M | -26.10M | -20.28M | -20.92M | -20.20M | -25.87M |
| Income towards Parent CompanyParent Net Inc | -17.05M | -14.58M | -18.66M | -13.44M | -20.11M | -14.19M | -21.68M | -21.24M | -29.49M | -25.92M | -32.66M | -26.10M | -20.28M | -20.92M | -20.20M | -25.87M |
| Net Income towards Common StockholdersNet Income | -17.05M | -14.58M | -18.66M | -13.44M | -20.11M | -14.19M | -21.68M | -21.24M | -29.49M | -25.92M | -32.66M | -26.10M | -20.28M | -20.92M | -20.20M | -25.87M |
| Additional items | ||||||||||||||||
| EPS (Basic) | -10.38 | -8.94 | -11.58 | -8.30 | -12.36 | -2.65 | -0.77 | -0.64 | -0.89 | -0.82 | -0.99 | -0.60 | -0.33 | -0.39 | -0.25 | -0.30 |
| EPS (Diluted) | -10.38 | -8.94 | -11.58 | -8.30 | -12.36 | -2.65 | -0.77 | -0.64 | -0.89 | -0.82 | -0.99 | -0.60 | -0.33 | -0.39 | -0.25 | -0.30 |
| Shares Outstanding | 1.64M | 1.63M | 1.61M | 1.62M | 1.63M | 5.35M | 27.98M | 33.00M | 33.06M | 31.79M | 33.11M | 43.57M | 60.98M | 53.65M | 81.18M | 85.63M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 1.64M | 1.63M | 1.61M | 1.62M | 1.63M | 5.35M | 27.98M | 33.00M | 33.06M | 31.79M | 33.11M | 43.57M | 60.98M | 53.65M | 81.18M | 85.63M |
| EBITDA | -17.48M | -15.20M | -19.29M | -13.97M | -20.27M | -14.97M | -23.29M | -23.55M | -31.54M | -27.38M | -33.80M | -30.69M | -21.65M | -23.12M | -22.33M | -28.02M |
| Interest ExpensesInt Expense | 0.03M | 0.05M | 0.05M | 0.05M | 0.05M | 0.05M | 0.04M | 0.04M | 0.04M | 0.03M | 0.03M | 0.03M | 0.02M | 0.02M | 0.02M | 0.01M |